Cargando…
Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative
Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden C...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505214/ https://www.ncbi.nlm.nih.gov/pubmed/36145611 http://dx.doi.org/10.3390/pharmaceutics14091863 |
_version_ | 1784796416347996160 |
---|---|
author | Kusic, Dara Heil, Jessica Zajic, Stefan Brangan, Andrew Dairo, Oluseun Smith, Gretchen Morales-Scheihing, Diego Buono, Russell J. Ferraro, Thomas N. Haroz, Rachel Salzman, Matthew Baston, Kaitlan Bodofsky, Elliot Sabia, Michael Resch, Alissa Scheinfeldt, Laura B. |
author_facet | Kusic, Dara Heil, Jessica Zajic, Stefan Brangan, Andrew Dairo, Oluseun Smith, Gretchen Morales-Scheihing, Diego Buono, Russell J. Ferraro, Thomas N. Haroz, Rachel Salzman, Matthew Baston, Kaitlan Bodofsky, Elliot Sabia, Michael Resch, Alissa Scheinfeldt, Laura B. |
author_sort | Kusic, Dara |
collection | PubMed |
description | Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination. |
format | Online Article Text |
id | pubmed-9505214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95052142022-09-24 Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative Kusic, Dara Heil, Jessica Zajic, Stefan Brangan, Andrew Dairo, Oluseun Smith, Gretchen Morales-Scheihing, Diego Buono, Russell J. Ferraro, Thomas N. Haroz, Rachel Salzman, Matthew Baston, Kaitlan Bodofsky, Elliot Sabia, Michael Resch, Alissa Scheinfeldt, Laura B. Pharmaceutics Article Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination. MDPI 2022-09-03 /pmc/articles/PMC9505214/ /pubmed/36145611 http://dx.doi.org/10.3390/pharmaceutics14091863 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kusic, Dara Heil, Jessica Zajic, Stefan Brangan, Andrew Dairo, Oluseun Smith, Gretchen Morales-Scheihing, Diego Buono, Russell J. Ferraro, Thomas N. Haroz, Rachel Salzman, Matthew Baston, Kaitlan Bodofsky, Elliot Sabia, Michael Resch, Alissa Scheinfeldt, Laura B. Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative |
title | Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative |
title_full | Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative |
title_fullStr | Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative |
title_full_unstemmed | Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative |
title_short | Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative |
title_sort | patient perceptions and potential utility of pharmacogenetic testing in chronic pain management and opioid use disorder in the camden opioid research initiative |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505214/ https://www.ncbi.nlm.nih.gov/pubmed/36145611 http://dx.doi.org/10.3390/pharmaceutics14091863 |
work_keys_str_mv | AT kusicdara patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT heiljessica patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT zajicstefan patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT branganandrew patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT dairooluseun patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT smithgretchen patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT moralesscheihingdiego patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT buonorussellj patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT ferrarothomasn patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT harozrachel patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT salzmanmatthew patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT bastonkaitlan patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT bodofskyelliot patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT sabiamichael patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT reschalissa patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative AT scheinfeldtlaurab patientperceptionsandpotentialutilityofpharmacogenetictestinginchronicpainmanagementandopioidusedisorderinthecamdenopioidresearchinitiative |